secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001104659-25-003801
Event type: regulatory
Sentiment:  neutral
Materiality: 0.15
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics receives and cures Nasdaq MVLS deficiency within days
-----------------------------------------------------------------------

- Received Nasdaq MVLS deficiency notice on Jan 8, 2025 for falling below $50M minimum from Nov 14 to Dec 27, 2024.
- Regained compliance as of Jan 14, 2025; Nasdaq confirmed compliance in writing on Jan 15, 2025.
- No immediate impact on listing; common stock continues trading on Nasdaq Global Market under GANX.
- Deficiency was cured within one week; matter is now closed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925003801/0001104659-25-003801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925003801/tm253348d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-003801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer